Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carsten Bokemeyer

Showing results (201-210 of 663) with videos related to

Pageof 67
Sort By:
Future Oncology (London, England)|March 5, 2019
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF studyHeinz Ludwig, Carsten Bokemeyer, Matti Aapro, et al.
Leukemia & Lymphoma|March 11, 2017
MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphomaNuray Akyüz, Nadine Albert-Konetzny, Christiane Pott, et al.
Hamostaseologie|February 9, 2024
Multisite Thrombosis in a Patient with Paroxysmal Nocturnal HemoglobinuriaLennart Beckmann, Tobias D Faizy, Fabian Flottmann, et al.
Leukemia & Lymphoma|August 8, 2023
The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysisFranziska Modemann, Paymon Ahmadi, Philipp H von Kroge, et al.
Diagnostic Pathology|July 26, 2015
Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancerNathaniel Melling, Johanna Muth, Ronald Simon, et al.
European Urology|June 28, 2011
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumorsKarin Oechsle, Christian Kollmannsberger, Friedemann Honecker, et al.
The Journal of Pathology|June 29, 2004
Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cellsFriedemann Honecker, Hans Stoop, Ronald R de Krijger, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2015
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)Pere Gascón, Matti Aapro, Heinz Ludwig, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2012
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsCarsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, et al.
Plos One|April 23, 2014
N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiencyLars Harbaum, Jan K Hennigs, Hans J Baumann, et al.
Pageof 67

Showing results (201-210 of 663) with videos related to

Sort By:
Pageof 67
Future Oncology (London, England)|March 5, 2019
Chemotherapy-induced neutropenia/febrile neutropenia prophylaxis with biosimilar filgrastim in solid tumors versus hematological malignancies: MONITOR-GCSF studyHeinz Ludwig, Carsten Bokemeyer, Matti Aapro, et al.
Leukemia & Lymphoma|March 11, 2017
MALT1 sequencing analyses in marginal zone B-cell lymphomas reveal mutations in the translocated MALT1 allele in an IGH-MALT1-positive MALT lymphomaNuray Akyüz, Nadine Albert-Konetzny, Christiane Pott, et al.
Hamostaseologie|February 9, 2024
Multisite Thrombosis in a Patient with Paroxysmal Nocturnal HemoglobinuriaLennart Beckmann, Tobias D Faizy, Fabian Flottmann, et al.
Leukemia & Lymphoma|August 8, 2023
The prognostic impact of lymphoma perforation in patients with primary gastrointestinal lymphoma - a single-center analysisFranziska Modemann, Paymon Ahmadi, Philipp H von Kroge, et al.
Diagnostic Pathology|July 26, 2015
Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancerNathaniel Melling, Johanna Muth, Ronald Simon, et al.
European Urology|June 28, 2011
Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumorsKarin Oechsle, Christian Kollmannsberger, Friedemann Honecker, et al.
The Journal of Pathology|June 29, 2004
Pathobiological implications of the expression of markers of testicular carcinoma in situ by fetal germ cellsFriedemann Honecker, Hans Stoop, Ronald R de Krijger, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 27, 2015
Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study)Pere Gascón, Matti Aapro, Heinz Ludwig, et al.
European Journal of Cancer (Oxford, England : 1990)|March 27, 2012
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trialsCarsten Bokemeyer, Eric Van Cutsem, Philippe Rougier, et al.
Plos One|April 23, 2014
N-terminal pro-brain natriuretic peptide is a useful prognostic marker in patients with pre-capillary pulmonary hypertension and renal insufficiencyLars Harbaum, Jan K Hennigs, Hans J Baumann, et al.
Pageof 67